Table 2.
Sequence (5′–3′) | Primer | Target | PCR product size (bp) | Source |
---|---|---|---|---|
GGGCTCTGGTCGTGATGT | Forward | ALS1 | 164 | This study |
GTGAGGGAATGAGTCTTG | Reverse | |||
ACTCGTGCCTATACCTAC | Forward | ALS2 | 80 | This study |
TTGTTGCCGTAATGGTGG | Reverse | |||
AGGTGCTGTAGTTGTTCTT | Forward | ALS3 | 81 | This study |
AGCAGTCGGGTTGAAAGG | Reverse | |||
TGGGCAGCACCAATCAAAT | Forward | LIP1 | 194 | This study |
GGGTAGACAATCGGGACA | Reverse | |||
TTGACTGTGCTCCTTCCT | Forward | LIP4 | 138 | This study |
GCTTTGGACCTTCGTAAT | Reverse | |||
TATGACAATGTGCCAGTT | Forward | SAP1 | 150 | This study |
TAAAGCAGTCAAAGTCCC | Reverse | |||
GCTGGTTTCTGTGCTTTG | Forward | SAP2 | 82 | This study |
CCACGTAGGCATGTCTTA | Reverse | |||
ACTTGGATTTCCAGCGAAGA | Forward | SAP3 | 165 | Silva et al., 2011a |
AGCCCTTCCAATGCCTAAAT | Reverse | |||
CTTCACCTCCTGGTTTCATTTC | Forward | SAP4 | 217 | This study |
TCAACTACCCATAAATCAGAGG | Reverse | |||
GACCGAAGCTCCAATGAATC | Forward | ACT1 | 181 | Silva et al., 2011a |
AATTGGGACAACGTGGGTAA | Reverse |